{"id":249536,"date":"2014-02-24T21:48:04","date_gmt":"2014-02-25T02:48:04","guid":{"rendered":"http:\/\/www.eugenesis.com\/exclusive-david-gancberg-article-in-human-gene-therapy\/"},"modified":"2014-02-24T21:48:04","modified_gmt":"2014-02-25T02:48:04","slug":"exclusive-david-gancberg-article-in-human-gene-therapy","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-engineering\/exclusive-david-gancberg-article-in-human-gene-therapy.php","title":{"rendered":"Exclusive David Gancberg article in Human Gene Therapy"},"content":{"rendered":"<p><p>    PUBLIC RELEASE DATE:  <\/p>\n<p>    24-Feb-2014  <\/p>\n<p>    Contact: Vicki Cohn    <a href=\"mailto:vcohn@liebertpub.com\">vcohn@liebertpub.com<\/a>    914-740-2100 x2156    Mary Ann Liebert, Inc.\/Genetic    Engineering News<\/p>\n<p>    New Rochelle, NY, February 24, 2014Over the past three funding    stages, the European Commission has invested nearly $475    million in 100 projects in the gene transfer and gene therapy    field. David Gancberg, Directorate-General for Research and    Innovation, European Commission (Brussels), describes the    substantial opportunities for funding to support basic and    clinical research in gene and cell therapy to find new    treatments for chronic and rare diseases and novel regenerative    medicine approaches in a Commentary article in Human Gene    Therapy, a peer-reviewed journal from Mary Ann Liebert,    Inc., publishers. The article is available free on the Human    Gene Therapy website.  <\/p>\n<p>    Dr. Gancberg and co-author Ruxandra Draghia-Akli state, \"More    than ever, the European Union offers to the gene and cell    therapy sectors the possibilities of financial support to    bright and innovative consortia ready to develop, possibly in    collaboration with industry, new therapeutic applications to be    tested in clinical trials, or novel products for the market,    and build sustainable networks of expertise in the field,\" in    their article \"Gene    and Cell Therapy Funding Opportunities in Horizon 2020: An    Overview 2014-2015.\"  <\/p>\n<p>    \"Funding for gene therapy provided by the European Commission    over the last decade has been critical to the current success    we are seeing in the clinics. The commentary provided by    doctors Gancberg and Draghia-Akli describe exciting new    programs.\" says James M. Wilson, MD, PhD, Editor-in-Chief of    Human Gene Therapy, and Director of the Gene Therapy    Program, Department of Pathology and Laboratory Medicine,    University of Pennsylvania Perelman School of Medicine,    Philadelphia.  <\/p>\n<p>    ###  <\/p>\n<p>    About the Journal  <\/p>\n<p>    Human Gene Therapy, the official journal of the European    Society of Gene and Cell Therapy, British Society for Gene and    Cell Therapy, French Society of Cell and Gene Therapy, German    Society of Gene Therapy, and five other gene therapy societies,    is an authoritative peer-reviewed journal published monthly in    print and online. Human Gene Therapy presents reports on    the transfer and expression of genes in mammals, including    humans. Related topics include improvements in vector    development, delivery systems, and animal models, particularly    in the areas of cancer, heart disease, viral disease, genetic    disease, and neurological disease, as well as ethical, legal,    and regulatory issues related to the gene transfer in humans.    Its sister journals, Human Gene Therapy Methods,    published bimonthly, focuses on the application of gene therapy    to product testing and development, and Human Gene Therapy    Clinical Development, published quarterly, features data    relevant to the regulatory review and commercial development of    cell and gene therapy products. Tables of content for all three    publications and a free sample issue may be viewed on the    Human Gene Therapy website.  <\/p>\n<p>    About the Publisher  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See the original post here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2014-02\/mali-ed022414.php\" title=\"Exclusive David Gancberg article in Human Gene Therapy\">Exclusive David Gancberg article in Human Gene Therapy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PUBLIC RELEASE DATE: 24-Feb-2014 Contact: Vicki Cohn <a href=\"mailto:vcohn@liebertpub.com\">vcohn@liebertpub.com<\/a> 914-740-2100 x2156 Mary Ann Liebert, Inc.\/Genetic Engineering News New Rochelle, NY, February 24, 2014Over the past three funding stages, the European Commission has invested nearly $475 million in 100 projects in the gene transfer and gene therapy field. David Gancberg, Directorate-General for Research and Innovation, European Commission (Brussels), describes the substantial opportunities for funding to support basic and clinical research in gene and cell therapy to find new treatments for chronic and rare diseases and novel regenerative medicine approaches in a Commentary article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-engineering\/exclusive-david-gancberg-article-in-human-gene-therapy.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[3],"tags":[],"class_list":["post-249536","post","type-post","status-publish","format-standard","hentry","category-genetic-engineering"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/249536"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=249536"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/249536\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=249536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=249536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=249536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}